<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03929510</url>
  </required_header>
  <id_info>
    <org_study_id>B7981011</org_study_id>
    <secondary_id>2018-003551-38</secondary_id>
    <nct_id>NCT03929510</nct_id>
  </id_info>
  <brief_title>Study to Characterize Absorption, Distribution, Metabolism and Excretion of 14C PF-06651600 and to Evaluate the Absolute Oral Bioavailability and Fraction Absorbed of PF-06651600.</brief_title>
  <acronym>B7981011</acronym>
  <official_title>A PHASE 1, OPEN-LABEL, NON-RANDOMIZED, 2-PERIOD, FIXED SEQUENCE STUDY TO INVESTIGATE THE ABSORPTION, DISTRIBUTION, METABOLISM AND EXCRETION OF 14C-PF-06651600 AND TO ASSESS THE ABSOLUTE BIOAVAILABILITY AND FRACTION ABSORBED OF PF-06651600 IN HEALTHY MALE PARTICIPANTS USING A 14C-MICROTRACER APPROACH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the absorption, distribution, metabolism and excretion (ADME) of
      14C PF-06651600 and characterize plasma, fecal and urinary radioactivity and identify any
      metabolites, if possible, of 14C PF-06651600 in humans.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 23, 2019</start_date>
  <completion_date type="Actual">July 5, 2019</completion_date>
  <primary_completion_date type="Actual">July 5, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mass Balance: Cumulative recovery (%) of radioactivity in urine</measure>
    <time_frame>from time zero to the time of last measurable concentration following oral administration of 14C PF-06651600 microtracer dose up to day 24</time_frame>
    <description>Cumulative recovery (%) of radioactivity in urine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mass Balance: Cumulative recovery (%) of radioactivity in feces</measure>
    <time_frame>from time zero to the time of last measurable concentration following oral administration of 14C PF-06651600 microtracer dose up to day 24</time_frame>
    <description>Cumulative recovery (%) of radioactivity in feces</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amount (% of the administered dose) of major metabolites of PF-06651600 in plasma</measure>
    <time_frame>Hour 0 up to 312 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount (% of the administered dose) of major metabolites of PF-06651600 in urine</measure>
    <time_frame>Hour 0 up to 312 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount (% of the administered dose) of major metabolites of PF-06651600 in feces</measure>
    <time_frame>Hour 0 up to 312 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Pre-dose, 0.25. 0.5, 1, 1.5, 2, 3.5, 4.5, 6.5, 8.5, 12.5, 24, 48, 72, 96 hours post-dose</time_frame>
    <description>Maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast</measure>
    <time_frame>Pre-dose, 0.25. 0.5, 1, 1.5, 2, 3.5, 4.5, 6.5, 8.5, 12.5, 24, 48, 72, 96 hours post-dose</time_frame>
    <description>Area under the plasma concentration time profile from time 0 to time of the last quantifiable concentration (Clast)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf</measure>
    <time_frame>Pre-dose, 0.25. 0.5, 1, 1.5, 2, 3.5, 4.5, 6.5, 8.5, 12.5, 24, 48, 72, 96 hours post-dose</time_frame>
    <description>Area under the plasma concentration time profile from time 0 to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Pre-dose, 0.25. 0.5, 1, 1.5, 2, 3.5, 4.5, 6.5, 8.5, 12.5, 24, 48, 72, 96 hours post-dose</time_frame>
    <description>Time for Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>Pre-dose, 0.25. 0.5, 1, 1.5, 2, 3.5, 4.5, 6.5, 8.5, 12.5, 24, 48, 72, 96 hours post-dose</time_frame>
    <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL (IV)</measure>
    <time_frame>Pre-dose, 0.25. 0.5, 1, 1.5, 2, 3.5, 4.5, 6.5, 8.5, 12.5, 24, 48, 72, 96 hours post-dose</time_frame>
    <description>Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood (rate at which a drug is metabolized or eliminated by normal biological processes). Clearance obtained after intravenous infusion dose (apparent clearance) is influenced by the fraction of the dose absorbed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F (oral)</measure>
    <time_frame>Pre-dose, 0.25. 0.5, 1, 1.5, 2, 3.5, 4.5, 6.5, 8.5, 12.5, 24, 48, 72, 96 hours post-dose</time_frame>
    <description>Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood (rate at which a drug is metabolized or eliminated by normal biological processes). Clearance obtained after intravenous infusion dose (apparent clearance) is influenced by the fraction of the dose absorbed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vss</measure>
    <time_frame>Pre-dose, 0.25. 0.5, 1, 1.5, 2, 3.5, 4.5, 6.5, 8.5, 12.5, 24, 48, 72, 96 hours post-dose</time_frame>
    <description>Steady state volume of distribution following IV infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F</measure>
    <time_frame>Pre-dose, 0.25. 0.5, 1, 1.5, 2, 3.5, 4.5, 6.5, 8.5, 12.5, 24, 48, 72, 96 hours post-dose</time_frame>
    <description>Apparent volume of distribution following oral administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total 14C_Urine_PO</measure>
    <time_frame>Pre-dose, Day1, day 2, day 3, day 4, day 5, day 6 and day 7 post-dose</time_frame>
    <description>Total radioactivity excreted into the urine from time zero to the time of last measurable concentration following oral administration of 14C PF 06651600 microtracer dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total 14C_Urine_IV</measure>
    <time_frame>Pre-dose, Day1, day 2, day 3, day 4, day 5, day 6 and day 7 post-dose</time_frame>
    <description>Total radioactivity excreted into the urine from time zero to the time of last measurable concentration following IV administration of 14C PF 06651600 microtracer dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE</measure>
    <time_frame>Baseline (Day 0) up to 90 days after last dose of study medication</time_frame>
    <description>Number of subjects and number of AEs which are any untoward medical occurrence regardless of attribution to study drug in a participant who received study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant changes to the physical examination</measure>
    <time_frame>Baseline (Day 0) up to Day 24</time_frame>
    <description>clinically significant changes to the physical examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Change From Baseline in Vital Signs</measure>
    <time_frame>Baseline (Day 0) up to Day 24</time_frame>
    <description>Vital signs (temperature, respiratory rate, pulse, systolic and diastolic blood pressure) obtained from each participant. Clinical significance of vital signs was determined at the investigator's discretion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities</measure>
    <time_frame>Baseline (Day 0) up to Day 24</time_frame>
    <description>Laboratory parameters include: hematological and chemical parameters</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Period A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of 200 mg 14C labeled PF-06651600 containing approximately 300 nCi 14C (ie, radiolabeled PF 06651600).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of 200 milligrams (mg) unlabeled PF-06651600 followed at time of peak plasma concentration (Tmax) by an Intravenous (IV) dose of 60 micrograms.14C -PF-06651600 containing approximately 300 nCi 14C (ie, radiolabeled PF-06651600).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>14C-PF-06651600</intervention_name>
    <description>Oral solution of 200 mg 14C labeled PF-06651600 containing approximately 300 nCi radioactivity</description>
    <arm_group_label>Period A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>14C-PF-06651600 IV</intervention_name>
    <description>IV solution 60 micrograms of 14C labeled PF-06651600 containing approximately 300 nCi radioactivity</description>
    <arm_group_label>Period B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06651600</intervention_name>
    <description>Oral solution 200mg</description>
    <arm_group_label>Period B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male participants who are healthy as determined by medical evaluation including a
             detailed medical history, full physical examination, including blood pressure (BP) and
             pulse rate (PR) measurement, 12 lead ECG, and clinical laboratory tests.

          -  Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lb).

        Exclusion Criteria:

          -  Known immunodeficiency disorder, including positive serology for human
             immunodeficiency virus (HIV) at screening, or a first degree relative with a
             hereditary immunodeficiency.

          -  Infection with hepatitis B or hepatitis C viruses.

          -  Participants with selected acute or chronic infections or infection history.

          -  Participants have a known present or a history of malignancy other than a successfully
             treated or excised non metastatic basal cell or squamous cell cancer of the skin.

          -  History of alcohol abuse or binge drinking and/or any other illicit drug use or
             dependence within 6 months of Screening.

          -  Use of tobacco/nicotine containing products within 3 months prior to dosing or
             positive urine cotinine test.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Only Male participants will be enrolled.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Groningen</city>
        <zip>9728 NZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PRA Health Sciences Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 BL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7981011&amp;StudyName=A+Phase+1%2C+Open-label%2C+Non-randomized%2C+2-period%2C+Fixed+Sequence+Study+To+Investigate+The+Absorption%2C+Distribution%2C+Metabolism+And+Excretion+Of+14c-pf-06651600+And+To+Assess+The+Absolute+Bioavailability+And+Fraction+Absorbed+Of+Pf-06651600+In+Healthy+Male+Participants+Using+A+14c-microtracer+Approach</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>April 17, 2019</study_first_submitted>
  <study_first_submitted_qc>April 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2019</study_first_posted>
  <last_update_submitted>July 23, 2019</last_update_submitted>
  <last_update_submitted_qc>July 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Male</keyword>
  <keyword>healthy</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

